Telo-HL

April 5, 2018April 5, 2018

Telo-HL Scoring Model Developed to Predict Relapse Risk in Hodgkin’s Patients, 3DS Says

News

3D Signatures’ Telo-HL test may be one step closer to clinical use with the development of a scoring model designed to predict the risk of relapse in Hodgkin’s lymphoma patients. The company ... Read more

June 14, 2017June 14, 2017

3D Signatures Advances Telo-HL Test to Determine Relapse Risk in Hodgkin’s Lymphoma Patients

News

A clinical trial validating Telo-HL‘s usefulness in determining the risk of relapse in Hodgkin’s lymphoma (HL) is underway, Canada’s 3D Signatures announced. This is Stage 3 of Telo-HL’s validation program. Both Stage 1, the ... Read more

April 4, 2017

Assay Validation of Hodgkin’s Lymphoma Test Completed by 3D Signatures

News

3D Signatures announced the completion of the assay validation of its Hodgkin’s lymphoma (HL) test, called Telo-HL, required under guidelines from the U.S. Food and Drug Administration (FDA). Telo-HL is powered by ... Read more